Previous studies have consistently shown that CD147-specific antibodies to the extracellular region can block TCR-mediated lymphocyte activation and proliferation.32, 33 Animal experiments have also revealed that the inhibition of CD147 by anti-CD147 mAb alleviated inflammation in mouse models of acute lung inflammation, asthma, and RA.20, 34–36 These data supported a potentially promising application of CD147 mAbs in the treatment of inflammatory diseases. This evidence concerns the gene BSG and rheumatoid arthritis.